These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28673834)

  • 1. Enzymatic O-GlcNAcylation of α-synuclein reduces aggregation and increases SDS-resistant soluble oligomers.
    Zhang J; Lei H; Chen Y; Ma YT; Jiang F; Tan J; Zhang Y; Li JD
    Neurosci Lett; 2017 Aug; 655():90-94. PubMed ID: 28673834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O-GlcNAcylation of α-Synuclein at Serine 87 Reduces Aggregation without Affecting Membrane Binding.
    Lewis YE; Galesic A; Levine PM; De Leon CA; Lamiri N; Brennan CK; Pratt MR
    ACS Chem Biol; 2017 Apr; 12(4):1020-1027. PubMed ID: 28195695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein.
    Levine PM; De Leon CA; Galesic A; Balana A; Marotta NP; Lewis YE; Pratt MR
    Bioorg Med Chem; 2017 Sep; 25(18):4977-4982. PubMed ID: 28487126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.
    Levine PM; Galesic A; Balana AT; Mahul-Mellier AL; Navarro MX; De Leon CA; Lashuel HA; Pratt MR
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1511-1519. PubMed ID: 30651314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease.
    Marotta NP; Lin YH; Lewis YE; Ambroso MR; Zaro BW; Roth MT; Arnold DB; Langen R; Pratt MR
    Nat Chem; 2015 Nov; 7(11):913-20. PubMed ID: 26492012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on α-synuclein aggregation.
    Ryan P; Xu MM; Davey AK; Kassiou M; Mellick GD; Rudrawar S
    Bioorg Chem; 2020 Jan; 94():103389. PubMed ID: 31753312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson's disease.
    Wani WY; Ouyang X; Benavides GA; Redmann M; Cofield SS; Shacka JJ; Chatham JC; Darley-Usmar V; Zhang J
    Mol Brain; 2017 Jul; 10(1):32. PubMed ID: 28724388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway.
    Cappai R; Leck SL; Tew DJ; Williamson NA; Smith DP; Galatis D; Sharples RA; Curtain CC; Ali FE; Cherny RA; Culvenor JG; Bottomley SP; Masters CL; Barnham KJ; Hill AF
    FASEB J; 2005 Aug; 19(10):1377-9. PubMed ID: 15946991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution.
    Li X; Dong C; Hoffmann M; Garen CR; Cortez LM; Petersen NO; Woodside MT
    Sci Rep; 2019 Feb; 9(1):1734. PubMed ID: 30741954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidation and nitration of α-synuclein and their implications in neurodegenerative diseases.
    Chavarría C; Souza JM
    Arch Biochem Biophys; 2013 May; 533(1-2):25-32. PubMed ID: 23454347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTY720 Nanoformulation Induces O-GlcNacylation of Synuclein to Alleviate Synucleinopathy.
    Sardoiwala MN; Boddu M; Biswal L; Karmakar S; Choudhury SR
    ACS Chem Neurosci; 2024 Jan; 15(1):71-77. PubMed ID: 38109795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O-GlcNAcylation inhibits the oligomerization of alpha-synuclein by declining intermolecular hydrogen bonds through a steric effect.
    Wu K; Li D; Xiu P; Ji B; Diao J
    Phys Biol; 2020 Dec; 18(1):016002. PubMed ID: 32906104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
    Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
    Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O-GlcNAc Modification of α-Synuclein Can Alter Monomer Dynamics to Control Aggregation Kinetics.
    Gamage K; Wang B; Hard ER; Van T; Galesic A; Phillips GR; Pratt M; Lapidus LJ
    ACS Chem Neurosci; 2024 Aug; 15(16):3044-3052. PubMed ID: 39082221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson's Diseases.
    Zhang J; Li X; Li JD
    Front Neurosci; 2019; 13():381. PubMed ID: 31057362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and topology of the non-amyloid-beta component fragment of human alpha-synuclein bound to micelles: implications for the aggregation process.
    Bisaglia M; Trolio A; Bellanda M; Bergantino E; Bubacco L; Mammi S
    Protein Sci; 2006 Jun; 15(6):1408-16. PubMed ID: 16731975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity.
    Xiang W; Schlachetzki JC; Helling S; Bussmann JC; Berlinghof M; Schäffer TE; Marcus K; Winkler J; Klucken J; Becker CM
    Mol Cell Neurosci; 2013 May; 54():71-83. PubMed ID: 23369945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.
    Alam P; Bousset L; Melki R; Otzen DE
    J Neurochem; 2019 Sep; 150(5):522-534. PubMed ID: 31254394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-translational modification of α-synuclein in Parkinson's disease.
    Barrett PJ; Timothy Greenamyre J
    Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.